Details of the Drug

General Information of Drug (ID: DMKEY6S)

Drug Name
Margetuximab
Indication
Disease Entry ICD 11 Status REF
HER2-positive breast cancer 2C60-2C65 Approved [1]
Gastric adenocarcinoma 2B72 Phase 2 [2]
Gastrointestinal cancer 2C11 Phase 2 [3]
Drug Type
Antibody
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 4120 mgday/L [4]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 466 mg/L [4]
Clearance
The clearance of drug is 0.22 L/day [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 19.2 days [4]
Metabolism
The drug is metabolized via the into smaller peptides through various proteases and catabolic pathways [4]
Vd
The volume of distribution (Vd) of drug is 5.47 L [4]
Cross-matching ID
DrugBank ID
DB14967
TTD ID
D01YYP
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Erbb2 tyrosine kinase receptor (HER2) TT6EO5L ERBB2_HUMAN Not Available [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease HER2-positive breast cancer
ICD Disease Classification 2C60-2C65
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Erbb2 tyrosine kinase receptor (HER2) DTT ERBB2 5.67E-03 -1.26 -2.05
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8686).
4 FDA Approved Drug Products: MARGENZA (margetuximab) injection